Enzon Pharmaceuticals (STU:EZ1) ROCE % : -1.85% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Enzon Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Enzon Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2023 was -1.85%.

Enzon Pharmaceuticals ROCE % Historical Data

The historical data trend for Enzon Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzon Pharmaceuticals ROCE % Chart

Enzon Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-9.41

-4.79

-1.02

-2.29

-2.24

Enzon Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-1.76	-2.46	-2.74	-1.95	-1.85

Enzon Pharmaceuticals ROCE % Calculation

Enzon Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-0.957	/	( ( (44.924 - 1.604)	+	(43.743 - 1.572) )	/ 2 )
	=	-0.957	/	( (43.32	+	42.171)	/ 2 )
	=	-0.957	/	42.7455
	=	-2.24 %

Enzon Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-0.792	/	( ( (44.036 - 0.38)	+	(43.743 - 1.572) )	/ 2 )
	=	-0.792	/	( ( 43.656	+	42.171 )	/ 2 )
	=	-0.792	/	42.9135
	=	-1.85 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Enzon Pharmaceuticals (STU:EZ1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Enzon Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Enzon Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzon Pharmaceuticals (STU:EZ1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (STU:EZ1) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ENZN:USA

Address

20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016

Website

http://www.enzon.com

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company earns revenue in the form of royalties. Primary source of royalty revenues derived from the sales of PegIntron, which is marketed by Merck.

Enzon Pharmaceuticals (STU:EZ1) Headlines

No Headlines